tbuckley/cabot-search huggingface dataset:
A5.09 Mri-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF
Authors: DM Boeters, WP Nieuwenhuis, MK Verheul, EC Newsum, REM Toes, LA Trouw, AHM van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> In patients with rheumatoid arthritis (RA) bone marrow oedema (BME) as observed by magnetic resonance imaging (MRI) represents osteitis with infiltration of leucocytes and an increased number of osteoclasts. Both BME and anti-citrullinated protein antibodies (ACPAs) are predictors of radiographic progression in RA and recent data indicate that ACPA can directly activate osteoclasts. These findings together lead to the hypothesis that ACPA is associated with BME; indeed, two small studies observed an association between BME and ACPA. Thus far the association of ACPA with other forms of MRI-detected inflammation (synovitis and tenosynovitis) has not been thoroughly explored. Furthermore, it is unknown if the association with MRI-detected inflammation is only present for ACPA or also for other RA-related auto-antibodies. This study addressed these questions. <h3>Materials and methods</h3> A total of 589 early arthritis patients, included in the Leiden Early Arthritis Clinic cohort, underwent contrast-enhanced 1.5T MRI of the unilateral wrist, metacarpophalangeal and metatarsophalangeal joints at baseline. BME, synovitis and tenosynovitis were scored according to the RAMRIS-method. ACPA, rheumatoid factor (RF) and anti-carbamylated protein (antiCarP) antibodies were determined at baseline. <h3>Results</h3> BME, synovitis and tenosynovitis were concomitantly present on MRI. In univariable analyses, ACPA-positive patients had higher BME-scores than ACPA-negative patients (median scores 4.5 vs. 2.0, p &lt; 0.001),&nbsp;but not more synovitis and tenosynovitis. Besides ACPA, also RF (median scores 3.75 vs 2.0, p &lt; 0.001) and anti-CarP antibodies (median scores 3.5 vs 2.5, p = 0.012) were associated with higher BME-scores in univariable analyses. To explore the association of the different antibodies with BME the BME-scores of patients with different auto-antibody combinations were compared. ACPA+RF-antiCarP- patients did not have higher BME-scores than ACPA-RF-antiCarP- patients, however ACPA+RF+antiCarP- and ACPA+RF+antiCarP+ patients had higher BME-scores (median 5.0 and 4.5 vs. 2.0 respectively, p &lt; 0.001 and p &lt; 0.001). ACPA and RF levels were not associated with BME-scores. <h3>Conclusions</h3> The presence and the level of ACPA alone were not associated with BME-scores. However, the combined presence of ACPA and RF did associate with more BME. This suggests an additive role of RF to ACPA in mediating osteitis.
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery
Authors: Derek J. Hausenloy, Luciano Candilio, Richard Evans, Cono Ariti, David P. Jenkins, Shyam Kolvekar, Rosemary Knight, Gudrun Kunst, Christopher Laing, Jennifer Nicholas, John Pepper, Steven Robertson, Maria Xenou, Tim Clayton, Derek M. Yellon
Journal: New England Journal of Medicine (2015)

Whether remote ischemic preconditioning (transient ischemia and reperfusion of the arm) can improve clinical outcomes in patients undergoing coronary-artery bypass graft (CABG) surgery is not known. We investigated this question in a randomized trial.We conducted a multicenter, sham-controlled trial involving adults at increased surgical risk who were undergoing on-pump CABG (with or without valve surgery) with blood cardioplegia. After anesthesia induction and before surgical incision, patients were randomly assigned to remote ischemic preconditioning (four 5-minute inflations and deflations of a standard blood-pressure cuff on the upper arm) or sham conditioning (control group). Anesthetic management and perioperative care were not standardized. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, coronary revascularization, or stroke, assessed 12 months after randomization.We enrolled a total of 1612 patients (811 in the control group and 801 in the ischemic-preconditioning group) at 30 cardiac surgery centers in the United Kingdom. There was no significant difference in the cumulative incidence of the primary end point at 12 months between the patients in the remote ischemic preconditioning group and those in the control group (212 patients [26.5%] and 225 patients [27.7%], respectively; hazard ratio with ischemic preconditioning, 0.95; 95% confidence interval, 0.79 to 1.15; P=0.58). Furthermore, there were no significant between-group differences in either adverse events or the secondary end points of perioperative myocardial injury (assessed on the basis of the area under the curve for the high-sensitivity assay of serum troponin T at 72 hours), inotrope score (calculated from the maximum dose of the individual inotropic agents administered in the first 3 days after surgery), acute kidney injury, duration of stay in the intensive care unit and hospital, distance on the 6-minute walk test, and quality of life.Remote ischemic preconditioning did not improve clinical outcomes in patients undergoing elective on-pump CABG with or without valve surgery. (Funded by the Efficacy and Mechanism Evaluation Program [a Medical Research Council and National Institute of Health Research partnership] and the British Heart Foundation; ERICCA ClinicalTrials.gov number, NCT01247545.).
Planning and Conducting Meetings Effectively, Part I
Authors: Jay Harolds
Journal: Clinical Nuclear Medicine (2011)

Meetings are held by leaders for many purposes, including conveying information, raising morale, asking for opinions, brain storming, making people part of the problem-solving process, building trust, getting to a consensus, and making decisions. However, many meetings waste time, some undermine the leader's power, and some decrease morale. Part I of this series of articles gives some tips on basic planning for decision-making meetings. Part II of this series of articles analyzes selected components of decision-making meetings. Part III of this series will be on how the chairperson keeps decision-making meetings on track to make them efficient and productive.
The New Look of Government
Authors: B. Duane
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article The New Look of Government Get access Betsy Duane Betsy Duane Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 3, 3 February 1993, Pages 185–187, https://doi.org/10.1093/jnci/85.3.185 Published: 03 February 1993
Abstract P6-07-01: CCN3 Impairs Osteoblasts and Stimulates Osteoclast Differentiation To Favor Breast Cancer Metastasis to Bone
Authors: E Amir, V Ouellet, A Mourskaia, K Tiedemann, J Fong, D Tran-Tanh, M Clemons, B Perbal, S Komorova, PM. Siegel
Journal: Cancer Research (2010)

Abstract Background: The mechanisms underlying the osteotropism of breast cancer are not fully understood. Breast cancer cell lines that aggressively metastasize to bone appear to have increased expression of CCN3 (Nov) compared to those that weakly metastasize to bone. This study aimed to functionally implicate CCN3 in the process of breast cancer metastasis to bone. Methods: Primary cultures of mouse bone marrow cells were used to assess the effect of recombinant CCN3 protein on RANKL, OPG and on osteoblasts and osteoclasts. To extend data obtained from cell and animal-based models, we have examined CCN3 expression a panel of human breast cancer bone metastases. Results: CCN3 protein impaired osteoblast differentiation in a dose dependant manner, resulting in an increase in the RANKL/OPG ratio that indirectly favors osteoclast formation. CCN3 also directly induced osteoclast differentiation of RANKL-primer RAW 264.7 monocytes. CCN3 enhanced osteoclast differentiation through its ability to induce calcium mobilization and the subsequent nuclear translocation of NFATc1, a transcription factor essential for osteoclast differentiation. Immunohistochemical staining indicated that CCN3 is readily detectable, both in the breast tumor/stroma and in the majority of breast cancer bone metastasis samples. Conclusion: Our data support a clinically relevant and important role for CCN3 in modulating the differentiation capacity of bone resident cells to support osteoclast formation and the formation of osteolytic bone metastases. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-07-01.
TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia
Authors: S Avigad, G Kuperstein, J Zilberstein, E Liberzon, B Stark, I Gelernter, Y Kodman, D Luria, S Ash, J Stein, Y Goshen, I Yaniv, IJ Cohen, R Zaizov
Journal: Leukemia (1999)
Abstract 2578: Efficacy of anti-CD22 antibody drug-conjugates in Ramos and Raji tumor xenograft models
Authors: Chin Pan, Colin Chong, Orville Cortez, Alison Witte, Ayesha Nazeer, Chetana Rao-Naik, Mary Huber, Alice Stevens, Qian Zhang, Asna Masood, Sanjeev Gangwar, David King, Brigitte Devaux, Pina Cardarelli
Journal: Cancer Research (2010)

Abstract CD22 is a well-validated target for immunotherapy on B cell tumors. CD22 is a B lymphoid lineage-specific differentiation antigen, and its cell surface expression coincides with IgD expression in human. CD22 expression is upregulated on mature B cells, and is lost upon terminal differentiation to plasma cells. CD22 is also highly expressed on B cell tumors including non-Hodgkin's lymphoma (NHL) and acute lymphocytic leukemia (ALL). Antibodies to CD22 rapidly internalize, making it an ideal target for an antibody drug conjugate (ADC) therapeutic approach. Human antibodies to CD22 have been generated. The antibodies bind B cells with high affinity and are rapidly internalized upon binding. Anti-CD22 conjugates linked to highly potent synthetic DNA minor-groove binding alkylating (MGBA) agents have been prepared and tested in vivo for the treatment of established Ramos and Raji subcutaneous tumor xenografts. Anti-tumor efficacy of the anti-CD22 conjugate was highly specific in comparison with the isotype control conjugate. The anti-CD22 conjugate at a single dose of 0.3 µmole/kg resulted in regression of established subcutaneous tumors with less than 5% body weight loss and no clinical signs of toxicity. The anti-CD22 conjugate at a single dose of 0.1 µmole/kg was more efficacious than Rituximab treatment on Ramos tumors. The anti-CD22 conjugate also had better tumor growth inhibition than an anti-CD19 conjugate. In summary, anti-CD22-ADCs have been prepared which show superior in vivo efficacy to Rituximab and to anti-CD19-ADCs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2578.
1267 BERBERINE ADMINISTRATION AMELIORATES NECROINFLAMMATION IN EXPERIMENTAL STEATOHEPATITIS INTERFERING WITH THE INFLAMMASOME PATHWAY, BUT IS ASSOCIATED WITH EXTRAHEPATIC TOXICITY
Authors: E. Vivoli, S. Milani, A. Provenzano, S. Madiai, E. Novo, M. Parola, F. Marra
Journal: Journal of Hepatology (2012)
Abstract B36: The Ewing's sarcoma fusion oncogene EWS-FLI1 induces tumors and developmental phenotypes in zebrafish
Authors: Stefanie W. Leacock, Audrey N. Basse, Garvin L. Chandler, Anne Kirk, James F. Amatruda
Journal: Cancer Research (2009)

Abstract Ewing's sarcoma, a member of the small round blue cell family of tumors, is an aggressive and malignant bone tumor of children and young adults. The cells are generally poorly differentiated, although can also have characteristics of neuroectodermal cells. Ewing's tumors are characterized by a t(11:22) that generates a fusion of the EWS protein and the FLI1 transcription factor. This fusion oncoprotein, EWS-FLI1, represents a potential therapeutic target for treatment of Ewing's sarcoma. However, the molecular mechanisms by which EWS-FLI1 mediates tumorigenesis remain unknown. Few animal models exist in which to study the function of EWS-FLI1. Here, we report the use of zebrafish as a new vertebrate model of EWS-FLI1 function and tumorigenesis. Using the zebrafish Tol2 transposon system, we have developed several transgenic models to study the function of EWS-FLI1 in a vertebrate model organism. First, we have injected zebrafish with transposons containing human EWS-FLI1 driven by either the heat shock or the β-actin promoter. A subset of the injected fish developed tumors when raised to adulthood. These tumors strongly resemble Ewing's sarcoma. This finding demonstrates that the functional targets of EWS-FLI1 that mediate tumor development are conserved from zebrafish to human. We observe an increased incidence of tumors in a p53 mutant background, suggesting that the p53 pathway may suppress EWS-FLI1 driven tumorigenesis. We are performing microarray analysis to identify candidate downstream effector genes and to compare to previously identified EWS-FLI1 target genes. In addition to these tumors, we identified transgenic lines that transmit the EWS-FLI1 transgene to their progeny. The embryos that express EWS-FLI1 exhibit abnormal embryonic development. This result suggests that EWS-FLI1 may regulate conserved developmental pathways. These transgenic lines represent a novel physiological context in which to study the cellular function of EWS-FLI1. From these two models of EWS-FLI1 expression in the zebrafish, we conclude that human EWS-FLI1 functions in zebrafish and that these models provide a novel context in which to study the function of this fusion oncogene. Additionally, the rapid development and small size of the zebrafish will allow us to utilize these models for genetic and chemical screens for specific EWS-FLI1 inhibitors for the treatment of Ewing's sarcoma. Citation Information: Cancer Res 2009;69(23 Suppl):B36.
UP TO ONE-YEAR FOLLOW-UP RESULTS FROM A MULTICENTER TRIAL OF A TRANSFEMORAL SYSTEM FOR MITRAL VALVE RECONSTRUCTION
Authors: Karl-Heinz Kuck, Francesco Maisano, Ottavio Alfieri, Antonio Colombo, Stephan Baldus, Alec Vahanian, Georg Nickenig
Journal: Journal of the American College of Cardiology (2016)
Pregnancy Poses Tough Questions For Cancer Treatment
Authors: J. Waalen
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Pregnancy Poses Tough Questions For Cancer Treatment Get access Jill Waalen Jill Waalen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 13, 3 July 1991, Pages 900–902, https://doi.org/10.1093/jnci/83.13.900 Published: 03 July 1991
Therapy of Lupus Nephritis
Authors: Howard A. Austin, John H. Klippel, James E. Balow, Nicole G.H. Le Riche, Alfred D. Steinberg, Paul H. Plotz, John L. Decker
Journal: New England Journal of Medicine (1986)

We evaluated renal function in 107 patients with active lupus nephritis who participated in long-term randomized therapeutic trials (median follow-up, seven years). For patients taking oral prednisone alone, the probability of renal failure began to increase substantially after five years of observation. Renal function was better preserved in patients who received various cytotoxic-drug therapies, but the difference was statistically significant only for intravenous cyclophosphamide plus low-dose prednisone as compared with high-dose prednisone alone (P = 0.027). The advantage of treatment with intravenous cyclophosphamide over oral prednisone alone was particularly apparent in the high-risk subgroup of patients who had chronic histologic changes on renal biopsy at study entry. Patients treated with intravenous cyclophosphamide have not experienced hemorrhagic cystitis, cancer, or a disproportionate number of major infections. We conclude that, as compared with high-dose oral prednisone alone, treatment of lupus glomerulonephritis with intravenous cyclophosphamide reduces the risk of end-stage renal failure with few serious complications. (N Engl J Med 1986;314:614–9.)
Management of Injuries in Children, by John F T Glasgow, H Kerr Graham
Authors: R. J Morton
Journal: BMJ (1997)

John F T Glasgow, H Kerr Graham: BMJ Publishing, £34.95, pp 423 ISBN 0 7279 0925 8

I should have saved this book for my holiday, as it is an ideal relaxation read. It is a background medical text, but each chapter is full of vignettes of medical history, illustrative cases, and interesting pictures. The authors are obviously practising clinicians and are keen to impart their knowledge.



Clear illustrations and a step by step text are the ingredients of Joint and Soft Tissue Injection: Injecting with Confidence by Trevor Silver (Radcliffe, £19.95, ISBN 1 85775 143 4). All the …
Aneurysm of the Iliac Artery Demonstrated on Tc-99m In Vitro Labeled Red Blood Cell Scintigraphy
Authors: ARIWAN RAKVIT, GARY MEYERROSE, LEIGH A. JENKINS, CHANWIT ROONGSRITONG, SOROT PHISITKUL, JAMES TSIKOURIS, RICK STATES, ROMIRO SANCHEZ
Journal: Clinical Nuclear Medicine (2003)

A 76-year-old man was examined for left lower extremity claudication. An angiogram revealed severely atherosclerotic vessels with a 2- to 3-cm aneurysm of the left iliac artery and a critical stenosis in the left femoral artery. After angioplasty and stent placement of the patient’s stenotic lesion, cardiac blood pool imaging was obtained to evaluate ventricular function. During imaging, the aneurysm of the left iliac artery was visualized on flow, planar, and SPECT images of the abdomen. These images show that medium size aneurysms of the peripheral vessels can be visualized using blood-pool images.
ADRENAL CORTICAL RESPONSES TO STRESS IN NORMAL MEN AND IN THOSE WITH PERSONALITY DISORDERS
Authors: GREGORY PINCUS, HUDSON HOAGLAND
Journal: American Journal of Psychiatry (1950)

1. Six indices of adrenal cortical activation have been compared in groups of normal male subjects and schizophrenic male patients when they were subjected to a variety of stresses. The indices are changes in output of urinary sodium, potassium, uric acid, 17-ketosteroids and neutral reducing lipids together with changes in the number of circulating lymphocytes. The stresses have been the target ball frustration test, operation of a pursuit meter (each test lasting one hour), the effects on our indices of adrenal cortical extract and of pituitary adrenocorticotrophin. 2. Responses of our 6 adrenal cortical indices and also eosinophile responses to injected adrenocorticotrophin were determined for groups of male and female psychoneurotic patients and compared to normal controls. 3. The tests all involved significant numbers of patients and controls and the results have been treated statistically. 4. Our data indicate a highly significant failure of normal adrenal stress responses in the schizophrenic population as compared with the control population. 5. The failure occurs principally at the level of the ability of the adrenal cortex to respond to adrenocorticotrophin. 6. This failure was not corrected by a dietary supplement rich in proteins and vitamins. 7. These findings are discussed in relation to the etiology of schizophrenia. 8. Psychoneurotic patients in contrast to schizophrenics respond in a normal fashion to injected adrenocorticotrophin.
Augmentation of Antiproliferative Activity of Interferon Alfa Against Human Bladder Tumor Cell Lines by Encapsulation of Interferon Alfa Within Liposomes
Authors: J. J. Killion, D. Fan, C. D. Bucana, D. N. Frangos, J. E. Price, I. J. Fidler
Journal: JNCI Journal of the National Cancer Institute (1989)

Present therapy for human bladder cancer includes the intravesical administration of antiproliferative agents, such as recombinant human Interferon alfa (IFN-α). The administration of cytotoxic molecules encapsulated in liposomes could provide a more efficient method for such therapy. Therefore, we determined whether encapsulation of the recombinant human IFN-α hybrid BBDD within lipo-somes will produce antitumor effects against the human bladder cancer cell line 253J superior to those observed with free IFN-α. Adherent cells were cultured in medium alone, in medium containing different concentrations of IFN-α, or in medium containing multilamellar liposomes (phosphatidylcholine-phosphatidylserine at a molar ratio of 7:3) that encapsulated saline or IFN-α. Cell growth was determined 96–120 hours later. Additional control groups consisted of target cells cultured with free IFN-α or with IFN-α plus liposomes containing saline. Cytostasis mediated by free IFN-α alone or IFN-α in the presence of liposome-saline was identical and ranged from 0%–30% (10 IU/mL) to 45%–70% (1,000 IU/mL). bposomes containing saline produced no effects. Liposome-encapsulated IFN-α produced significantly greater growth inhibition than free IFN-α: 40%–70% (10 IU/mL) and 80%–90% (1,000 IU/mL), respectively. Moreover, a 253J variant sublime selected for resistance to free IFN-α was sensitive to IEN-α presented in liposomes. These data suggest that the encapsulation of antiproliferative agents such as IEN-α in liposomes can improve therapeutic results. (J Natl Cancer Inst 81:1387–1392, 1989]
Attempt Made to “Immunize” Patients Against Their Cancer
Authors: Susan Jenks
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Attempt Made to “Immunize” Patients Against Their Cancer Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 21, 6 November 1991, Page 1532, https://doi.org/10.1093/jnci/83.21.1532 Published: 06 November 1991